Currently, the only drugs that radically cure Plasmodium vivax malaria are 8-aminoquinoline–based drugs, which can cause hemolysis in G6PD-deficient patients. Therefore, determination of G6PD level is critical before treatment. This study evaluated tests for G6PD deficiency, including validating the correlation of quantitative reference assays, and establishing recombinant G6PD controls.
Author(s): Pal S, LaRue N, Hrutkay S, Barney B, Kahn M, Bansil P, Kalnoky M, LeaderT, Domingo G
Corporate author(s): PATH
Publication date: November 2017
301 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
This publication is part of the series ASTMH posters
Related regions: Global
- About PATH's work > Strengthening health systems
- Emerging and epidemic diseases > Malaria
- Health technologies > Diagnostics
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA